Literature DB >> 8077319

Insulin secretion, clearance, and action on glucose metabolism in cirrhotic patients.

M R Letiexhe1, A J Scheen, P L Gérard, B H Bastens, J Pirotte, J Belaiche, P J Lefèbvre.   

Abstract

To study the mechanisms of glucose intolerance and hyperinsulinism in liver cirrhosis, we compared the plasma glucose, insulin, and C-peptide levels during a frequently sampled i.v. glucose tolerance test (0.3 g glucose/kg BW) in nine compensated cirrhotic patients and nine healthy volunteers well matched for age, sex, and body weight. The insulin secretion rate was derived by the deconvolution of plasma C-peptide levels, insulin sensitivity was calculated using Bergman's minimal model method, and insulin clearance was estimated by dividing the 0-180 min area under the curve of insulin secretion rate by that of peripheral plasma insulin levels. The cirrhotic patients were characterized during the frequently sampled i.v. glucose tolerance test by a 60% greater insulin secretion rate (P < 0.05), a markedly reduced insulin sensitivity index (SI; 2.82 +/- 0.75 vs. 5.86 +/- 0.68 x 10(-4) min/mU.L; P < 0.01) and a 40% reduced insulin clearance (725 +/- 169 vs. 1165 +/- 99 mL/min.m-2; P < 0.05). The reduction of insulin clearance was significantly correlated with the amplitude of the portosystemic shunt, measured using an isotopic method (r = 0.75; P < 0.02). In conclusion, cirrhosis is characterized by an important peripheral hyperinsulinism, resulting from both a higher insulin secretion rate and a reduced insulin hepatic clearance; the severe insulin resistance explains the glucose metabolism alterations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8077319     DOI: 10.1210/jcem.77.5.8077319

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Renal impairment in cirrhosis unrelated to hepatorenal syndrome.

Authors:  Gavin Low; Graeme Jm Alexander; David J Lomas
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04-15

Review 2.  Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy.

Authors:  Diego García-Compeán; José Alberto González-González; Fernando Javier Lavalle-González; Emmanuel Irineo González-Moreno; Jesús Zacarías Villarreal-Pérez; Héctor J Maldonado-Garza
Journal:  Dig Dis Sci       Date:  2016-02       Impact factor: 3.199

Review 3.  Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Investig       Date:  1994-08

4.  Mechanisms of hyperinsulinaemia in Child's disease grade B liver cirrhosis investigated in free living conditions.

Authors:  A V Greco; G Mingrone; A Mari; E Capristo; M Manco; G Gasbarrini
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

5.  Plasma leptin levels, insulin secretion, clearance and action on glucose metabolism in anorexia nervosa.

Authors:  M R Letiexhe; A J Scheen; P J Lefèbvre
Journal:  Eat Weight Disord       Date:  1997-06       Impact factor: 4.652

6.  Insulin sensitivity and variability in hepatitis C virus infection using direct measurement.

Authors:  Nizar A Mukhtar; Peter Bacchetti; Claudia E Ayala; Jennifer Melgar; Spencer Christensen; Jacquelyn J Maher; Mandana Khalili
Journal:  Dig Dis Sci       Date:  2012-10-21       Impact factor: 3.199

Review 7.  Kidneys in chronic liver diseases.

Authors:  Marek Hartleb; Krzysztof Gutkowski
Journal:  World J Gastroenterol       Date:  2012-06-28       Impact factor: 5.742

8.  Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD.

Authors:  Ian H de Boer; Leila Zelnick; Maryam Afkarian; Ernest Ayers; Laura Curtin; Jonathan Himmelfarb; T Alp Ikizler; Steven E Kahn; Bryan Kestenbaum; Kristina Utzschneider
Journal:  J Am Soc Nephrol       Date:  2016-01-28       Impact factor: 10.121

Review 9.  Cephalic phase insulin release: A review of its mechanistic basis and variability in humans.

Authors:  Alexa J Pullicin; John I Glendinning; Juyun Lim
Journal:  Physiol Behav       Date:  2021-07-09

10.  Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia.

Authors:  Martin Whyte; Alberto Quaglia; David Hopkins
Journal:  Clin Case Rep       Date:  2015-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.